Final combined fill volume [pending] · Pack imagery represents current concept and is subject to change.
AUREVIA CD//FLOW
Practitioner circulation system for endothelial wellness, nitric oxide and fibrinolytic balance.
AUREVIA CD//FLOW pairs HPβCD in a citrulline-forward aqueous matrix with a phyto-active phospholipid phase carrying nattokinase, beetroot and pine bark extracts. The formulation is designed for practitioner-guided use in adults seeking targeted circulation, endothelial and fibrinolytic-balance support.
Not available for purchase until finished-product validation is complete.
Cyclodextrin intelligence. Liposomal precision.
Each daily unit contains two connected chambers — a purified aqueous cyclodextrin matrix and a separately manufactured phospholipid phase — combined only at the moment of use.
Phase One — Citrulline Matrix
- HPβCDPending regulatory & safety review
- Advanced cyclodextrin-research component
- Analytical inclusion platform
- L-Citrulline
- Nitric-oxide precursor pathway
- Endothelial wellness positioning
- Practitioner-guided circulation support
- Purified water · vegetable glycerin · buffer system
- Aqueous carrier, viscosity, palatability and stability
Phase Two — Phyto-Active Delivery
- Nattokinase (verified activity units)
- Fibrinolytic-balance research relevance
- Practitioner-guided circulation support
Do not use with anticoagulant or antiplatelet medication unless specifically approved by the prescribing clinician.
- Standardised beetroot extract
- Dietary nitrate contribution
- Vascular-wellness positioning
- Pine bark extract (standardised OPCs)
- Polyphenol antioxidant
- Endothelial-wellness research relevance
- Sunflower phosphatidylcholine
- Cholesterol-free liposomal carrier
- Disperses lipid-compatible phyto-actives
- Natural mixed tocopherols
- Oxidative protection of the phospholipid phase
Designed to support.
Proposed structure/function positioning. Requires final formulation-specific substantiation and regional regulatory approval.
- Endothelial wellness
- Nitric-oxide pathway support
- Fibrinolytic balance research
- Vascular-wellness routines under practitioner guidance
Designed for use inside a practitioner protocol — not a self-prescribed daily basic.
L-citrulline in Phase One paired with dietary nitrate from beetroot in Phase Two.
Nattokinase delivered in the phospholipid phase, kept separate from the cyclodextrin matrix.
Standardised pine bark OPCs in the phyto-active phase.
Nothing hidden.
Final quantities are declared once formulation and regulatory review are complete.
| Ingredient | Role | Per serving | Evidence |
|---|---|---|---|
| HPβCD | Advanced cyclodextrin research | TBC | Mechanistic |
| L-Citrulline | Nitric-oxide precursor | TBC | Emerging |
| Nattokinase | Fibrinolytic research | TBC (FU/serving) | Emerging |
| Beetroot extract (standardised) | Dietary nitrate | TBC | Emerging |
| Pine bark extract (standardised) | Endothelial OPCs | TBC | Emerging |
| Sunflower phosphatidylcholine | Cholesterol-free liposomal carrier | TBC | Established |
A practitioner-guidance formulation built around endothelial and circulation pathways.
Not sold as a self-directed daily wellness item. Labelling and pack copy will direct consumers to qualified practitioner guidance.
Nattokinase and lipid-soluble phyto-actives are stored away from the HPβCD-bearing aqueous phase to protect activity and inclusion behaviour.
Cautions for anticoagulant and antiplatelet medication are prominent, not buried.
- Adults working with a qualified practitioner
- Consumers focused on endothelial and circulation-pathway support
- Practitioners looking for a differentiated multi-pathway circulation format
- Existing users of nitric-oxide precursors seeking a more considered format
Consult a qualified healthcare professional before use if you:
- Are pregnant or breastfeeding
- Take prescription medication
- Have kidney or liver disease
- Have diagnosed cardiovascular disease
- Use lipid-lowering medication
- Are receiving specialist medical care
- Are preparing for surgery or another medical procedure
- Have experienced sensitivity to cyclodextrins or formulation ingredients
Do not discontinue or replace prescribed treatment.
Questions we get, answered honestly.
Can I take CD//FLOW if I use blood thinners?+
Not without specific clearance from your prescribing clinician. Nattokinase can affect fibrinolytic pathways relevant to anticoagulant and antiplatelet therapy.
Is CD//FLOW a treatment for cardiovascular disease?+
No. It is not a treatment for any disease and does not replace prescribed medication.
Why is it called a practitioner system?+
Because appropriate use, dose, timing and combination with other therapies is best assessed by a qualified practitioner.
Is the finished product clinically tested?+
Not yet. Ingredient-level research exists but is not equivalent to finished-product trials.
The rest of the DualPhase™ collection.
Dual-cyclodextrin lipid pathway formula. The foundation of the AUREVIA DualPhase™ platform.
Advanced cardiovascular longevity formula. Multi-pathway wellness across two precisely separated phases.